Impax Labs announced the July 30, 2004 approval of an Abbreviated New Drug Application (ANDA 076249) from the FDA, marking a significant milestone for its generic portfolio. This service-launch clearance is expected to have an immediate and positive impact on the company’s revenue streams following the entry of copy products into the market.